Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

被引：85

作者：

Brauch, Hiltrud ^{[1
,2
]}

Schroth, Werner ^{[1
,2
]}

Goetz, Matthew P. ^{[3
]}

Muerdter, Thomas E. ^{[1
,2
]}

Winter, Stefan ^{[1
,2
]}

Ingle, James N. ^{[3
]}

Schwab, Matthias ^{[1
,2
,4
]}

Eichelbaum, Michel ^{[1
,2
]}

机构：

[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[2] Univ Tubingen, Tubingen, Germany

[3] Mayo Clin, Rochester, MN USA

[4] Univ Tubingen Hosp, Inst Expt & Clin Pharmacol & Toxicol, Tubingen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 02期

关键词：

GROUP; 1-98; TRIAL; METABOLITE PLASMA-CONCENTRATIONS; REUPTAKE INHIBITOR PAROXETINE; ESTROGEN-RECEPTOR; ACTIVE METABOLITE; RE CYP2D6; ADJUVANT TAMOXIFEN; UGT2B7; GENOTYPE; WOMEN; POLYMORPHISMS;

D O I：

10.1200/JCO.2012.44.6625

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：176 / 180

页数：5

共 36 条

[1] CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen [J].

Abraham, Jean E. ;

Maranian, Mel J. ;

Driver, Kristy E. ;

Platte, Radka ;

Kalmyrzaev, Bolot ;

Baynes, Caroline ;

Luccarini, Craig ;

Shah, Mitul ;

Ingle, Susan ;

Greenberg, David ;

Earl, Helena M. ;

Dunning, Alison M. ;

Pharoah, Paul D. P. ;

Caldas, Carlos .

BREAST CANCER RESEARCH, 2010, 12 (04)

[2] Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score [J].

Barginear, M. F. ;

Jaremko, M. ;

Peter, I. ;

Yu, C. ;

Kasai, Y. ;

Kemeny, M. ;

Raptis, G. ;

Desnick, R. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) :605-611

[3] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].

Borges, Silvana ;

Desta, Zeruesenay ;

Li, Lang ;

Skaar, Todd C. ;

Ward, Bryan A. ;

Nguyen, Anne ;

Jin, Yan ;

Storniolo, Anna Maria ;

Nikoloff, D. Michele ;

Wu, Lin ;

Hillman, Grant ;

Hayes, Daniel F. ;

Stearns, Vered ;

Flockhart, David A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74

[4] Pharmacogenomics of Tamoxifen Therapy [J].

Brauch, Hiltrud ;

Muerdter, Thomas E. ;

Eichelbaum, Michel ;

Schwab, Matthias .

CLINICAL CHEMISTRY, 2009, 55 (10) :1770-1782

[5] Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach? [J].

Brauch, Hiltrud ;

Jordan, V. Craig .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) :2274-2283

[6]

Castells A, 2000, CANCER RES, V60, P2836

[7] A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers [J].

Decensi, A ;

Robertson, C ;

Viale, G ;

Pigatto, F ;

Johansson, H ;

Kisanga, ER ;

Veronesi, P ;

Torrisi, R ;

Cazzaniga, M ;

Mora, S ;

Sandri, MT ;

Pelosi, G ;

Luini, A ;

Goldhirsch, A ;

Lien, EA ;

Veronesi, U .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (11) :779-790

[8] Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen [J].

Dowsett, M ;

Haynes, BP .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) :255-263

[9] Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes [J].

Goetz, MP ;

Rae, JM ;

Suman, VJ ;

Safgren, SL ;

Ames, MM ;

Visscher, DW ;

Reynolds, C ;

Couch, FJ ;

Lingle, WL ;

Flockhart, DA ;

Desta, Z ;

Perez, EA ;

Ingle, JN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9312-9318

[10] Allelic losses as prognostic markers for breast cancers [J].

Hirano A. ;

Utada Y. ;

Haga S. ;

Kajiwara T. ;

Sakamoto G. ;

Kasumi F. ;

Nakamura Y. ;

Emi M. .

International Journal of Clinical Oncology, 2001, 6 (1) :6-12

← 1 2 3 4 →